Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Key Clinical Message: We report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring mutations in both exons 11 and 9. The significance of this co-occurrence is unknown and might increase the responsiveness of gastrointestinal stromal tumors (GISTs) to imatinib.
Abstract: pCR of GIST to neoadjuvant imatinib is rare. We report a case of pCR to neoadjuvant imatinib in a gastric stromal tumor that harbored co-occurrence of multiple mutations in exons 11 and 9. This co-occurrence in exons 9 and 11 is the first to be reported in the English literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248213 | PMC |
| http://dx.doi.org/10.1002/ccr3.7463 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for fusion.
Front Oncol
August 2025
Department of Internal Medicine, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with proto-oncogene, receptor tyrosine kinase (c-kit), or PDGFRα mutations detected in around 85% of cases. GISTs without c-kit or platelet-derived growth factor receptor alpha (PDGFRα) mutations are considered wild-type (WT). Recently, some molecular alterations, including neurotrophic tyrosine receptor kinase (NTRK) fusions, have been reported in very few cases of WT GISTs.
View Article and Find Full Text PDF[A Case of Lower Rectal GIST with Anorectal Preservation by Laparoscopic Low Anterior Resection after Imatinib Mesylate Neoadjuvant Therapy].
Gan To Kagaku Ryoho
July 2025
Dept. of Surgery, Toyonaka Keijinkai Hospital.
A 60-year-old man was diagnosed with a rectal gastrointestinal stromal tumor(GIST). Endoscopy revealed a submucosal tumor in the lower rectum near the dentate line. CT and MRI findings showed that the tumor was compressing the prostate and seminal vesicles.
View Article and Find Full Text PDFCase Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice.
Front Oncol
July 2025
Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States.
Neoadjuvant chemoimmunotherapy has become an established treatment approach in resectable non-small cell lung cancer (NSCLC). The utilization of neoadjuvant immune checkpoint blockade (ICB) and coordination of care in the real-world setting present important challenges, with limited data available for patients with multiple synchronous primary malignancies. This case describes a 57-year-old man with simultaneous diagnoses of resectable stage IIIA NSCLC and -rearranged myeloid neoplasm who received neoadjuvant chemotherapy and nivolumab in combination with imatinib prior to definitive resection.
View Article and Find Full Text PDF[Neoadjuvant imatinib treatment of locally advanced gastrointestinal stromal tumours: Theory and practice].
Bull Cancer
September 2025
Département d'oncologie médicale, centre Oscar-Lambret, 3, rue Combemale, 59020 Lille cedex, France.
In this review we summarised published clinical trials evaluating neoadjuvant treatment with imatinib for locally advanced gastro-intestinal stromal tumours. We illustrate the practice through a clinical vignette, allowing us to highlight practical suggestions.
View Article and Find Full Text PDFManagement of a large abdominal dermatofibrosarcoma protuberans requiring a life-threatening excision: A case report.
Int J Surg Case Rep
August 2025
University Institute of Locomotor and Sport (IULS), Pasteur Hospital, Nice, France; Laboratory of Molecular PhysioMedicine (LP2M), UMR 7370, CNRS, University Côte d'Azur, Nice, France. Electronic address:
Introduction And Importance: Dermatofibrosarcoma protuberans (DFSP) is a rare malignant tumor of the dermis and subcutaneous tissue, characterized by local aggressiveness and a high recurrence rate. The gold standard treatment is wide excision with negative margins, sometimes using Mohs surgery, with careful planning for reconstruction. In challenging cases, neoadjuvant imatinib therapy and adjuvant radiotherapy may help optimize outcomes.
View Article and Find Full Text PDF